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Abstract
Background: Shenmai injection (SM), as a traditional Chinese medicine injection, is widely used for chronic cor
pulmonale heart failure in mainland China. It is essential to systematically assess the efficacy and safety of SM as an
adjuvant treatment for chronic cor pulmonale heart failure.
Methods: Eight English and Chinese electronic databases were searched, from inception to December 2014, to identify
randomized controlled trials (RCTs) of SM for chronic cor pulmonale heart failure. The Cochrane Risk of Bias tool was
used to evaluate the methodological quality of eligible studies. Meta-analysis was performed by Review Manager 5.2.
Results: Twenty-seven RCTs with 2045 participants were identified. The methodological quality of the included studies
was generally low. Only one trial reported data on death. None of the included trials reported quality of life. The
meta-analysis indicated that compared to conventional treatment, the combination of SM and conventional treatment
was more effective in terms of the New York Heart Association classification (RR, 1.26; 95 % CI, 1.20–1.32; P < 0.00001),
Left Ventricular Ejection Fraction (MD, 11.33; 95 % CI, 8.59–14.07; p < 0.00001), partial pressure of oxygen (MD, 1.00; 95 %
CI, 0.64–1.36; P < 0.00001) and partial pressure of carbon dioxide (MD, 0.83; 95 % CI, 0.58–1.08; p < 0.00001). In addition,
two trials reported that SM plus conventional treatment was superior to the conventional treatment alone to
reduce B-type natriuretic peptide. No serious adverse drug events or reactions were reported.
Conclusions: SM plus conventional treatment appeared to be effective and relatively safe for chronic cor pulmonale
heart failure. However, due to the generally low methodological quality and small sample size, this review didn’t find
evidence to support routine use of SM as an adjuvant treatment for chronic cor pulmonale heart failure.
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Background
Chronic cor pulmonale, a common type of heart disease,
is a rising major public health problem around the
world. Although the term “cor pulmonale” is popular in
the medical literature, there is presently no consensual
definition. Chronic cor pulmonale may be defined as:
pulmonary hypertension results in right ventricular en-
largement (hypertrophy and/or dilatation), and may lead
with time to chronic cor pulmonale heart failure [1].
Chronic obstructive pulmonary disease (COPD) is by far
the main cause of chronic pulmonary heart disease [2].
Pulmonary hypertension resulting from disorders of the
respiratory system and/or from chronic hypoxaemia is
the main pathological mechanism of chronic cor pulmo-
nale [1, 3]. Chronic cor pulmonale, especially chronic cor
pulmonale heart failure, threatens people’s health and
quality of life worldwide.
The conventional medical treatment for chronic cor
pulmonale heart failure includes antibiotics, expectorants,
antiasthmatic drugs, oxygen therapy, diuretics, digi-
talis, vasodilators, antiarrhythic drugs and anticoagu-
lants. Western medicine is the dominating medical
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treatment for chronic cor pulmonale heart failure. However,
the treatment is still unsatisfactory now. Moreover, it is uni-
versally acknowledged that long-time use of western medi-
cine sometimes can cause side effects and drug resistance.
Shenmai injection (SM), as a traditional Chinese medi-
cine injection, derives from a traditional decoction named
Shenmai yin prescribed by a famous traditional Chinese
medicine doctor named Si-miao Sun in the Tang Dynasty.
It is a traditional Chinese herbal medicine that has been
used for patients with qi-yin deficiency in China for about
1500 years, consisting of Panax ginseng and Ophiopogon
japonicus. Panax ginseng, a plant belonging to araliaceae,
mainly grows in northeast China, which can strengthen
vital qi and is usually used for patients with qi deficiency,
while Ophiopogon japonicus, a plant belonging to lilia-
ceae, mainly grows in south China, which can nourish yin
and is usually used for patients with yin deficiency.
Shenmai injection (SM) has been approved by China
Food and Drug Administration (CFDA) on the market
for chronic cor pulmonale heart failure since 1995. The
drug instruction shows that SM can be administered
intramuscularly 2 to 4 ml once daily, or intravenously 20
to 100 ml once daily. According to traditional Chinese
medicine (TCM) theory, SM benefits qi, nourishes yin,
and replenishes bodily fluids. It is widely used for the
treatment of qi-yin deficiency in shock, coronary heart
disease, chronic pulmonary heart disease, viral myocar-
ditis, and malignant diseases [4]. The relatively higher
active components of SM are ginsenoside Rb1, Rb2, Rc,
Rd, Re, Rg1, and Ophiopogon saponin D [5]. Recent
pharmacological research reported that SM has protect-
ive effects against cardiac dysfunction [6, 7]. Recent clin-
ical research showed that SM can improve respiratory
function and left ventricular systolic function in patients
with chronic cor pulmonale [8].
A large number of clinical trials showed that SM bene-
fited patients with chronic cor pulmonale heart failure.
The previous systematic review [9] reported that SM
might have potential therapeutic effects for chronic pul-
monary heart disease. However, evidence was very lim-
ited on the efficacy and safety of SM for chronic cor
pulmonale heart failure of different severity, due to lack
of detailed description about the New York Heart Asso-
ciation (NYHA) classification and poor methodological
quality. One recent study [10] reported that SM could
improve the Left Ventricular Ejection Fraction (LVEF) in
gerontal patients with chronic heart failure. The other
recent study [11] showed that for chronic cor pulmonale
patients, admission high B-type natriuretic peptide (BNP)
levels are a high risk factor for subsequent readmission,
more intensive treatments are needed in patients with
higher BNP levels. But the previous systematic review
didn’t assess the effects of SM as an adjuvant treatment
on LVEF and BNP in patients with chronic cor pulmonale
heart failure. Therefore, it is necessary to assess systemat-
ically and critically the efficacy and safety of SM as an ad-
juvant treatment for chronic cor pulmonale heart failure.
Methods
This systematic review was reported in accordance with
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) [12]. The PRISMA 2009 check-
list for this systematic review and meta-analysis was listed
in Additional file 1.
Inclusion criteria
Two authors (LW Shi and YH Luo) independently ex-
amined the titles and abstracts of the trials to evaluate
their appropriateness for inclusion, based on the prede-
signed inclusion criteria. If there was uncertainty about
inclusion of the trial, we would retrieve the full text to
determine whether the trial should be included. The tri-
als that met the following inclusion criteria were in-
cluded: (1) types of studies: all randomized controlled
trials (RCTs) of SM for chronic cor pulmonale heart fail-
ure; (2) types of participants: patients who were diag-
nosed as chronic cor pulmonale heart failure with
NYHA classification from I to IV; (3) types of interven-
tions: SM was combined with conventional medical
treatment, compared to conventional medical treatment
alone, and SM was used by intravenous drip; (4) the pri-
mary outcome measures included death from any cause
during the scheduled treatment and follow-up and quality
of life as measured by various instruments; the secondary
outcome measures included NYHA classification, LVEF,
BNP, partial pressure of oxygen (PaO2) and partial pres-
sure of carbon dioxide (PaCO2), and adverse drug events
(ADEs) or adverse drug reactions (ADRs) during the
scheduled treatment and follow-up; (5) the studies con-
tained available and relevant data for meta-analysis; (6)
the studies were available in any language. Any disagree-
ment was resolved by consensus or discussion with a third
party (YM Xie and X Liao).
Exclusion criteria
If involved any condition of the followings, trials were
excluded: (1) duplicated publications; (2) data was un-
available or incorrect, or no relevant data for meta-
analysis; (3) quasi-randomized controlled clinical trials
(that is, allocation using alternation, the sequence of
admission, case record numbers, dates of birth), non-
randomized controlled clinical trials; (4) the patients
were diagnosed as chronic cor pulmonale heart failure
with unclear NYHA classification; (5) patients with co-
morbidities of coronary heart disease or severe liver
and kidney diseases; (6) combined with any other
herbal medicines in experimental or control group
during the treatment.
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Search strategy
A comprehensive search was performed to identify all
published randomized controlled clinical trials. All rele-
vant studies were sought regardless of any language.
The relevant trials were retrieved from the following
databases: the Cochrane Central Register of Controlled
Trials (CENTRAL) on the Cochrane Library (Issue 10
of 12, December 2014); PubMed (1966 to December
2014); EMBASE (1980 to December 2014); Chinese
Biomedical Literature Database (CBM, 1978 to October
2014); Chinese Scientific Journal Database (VIP, 1989 to
October 2014); Wan Fang Database (1990 to October
2014); and Chinese National Knowledge Infrastructure
(CNKI, 1979 to October 2014). Ongoing registered clinical
trials were searched in the Clinical Trials, gov (http: //
clinical trials. gov//). All of these searches ended on 7
December, 2014. The following search terms were used
individually or combined: “chronic cor pulmonale heart
failure”, “chronic cor pulmonale with cardiac dysfunction”,
“chronic cor pulmonale with cardiac insufficiency”, “Shen-
mai injection”, and “Shenmai”. The literature search was
performed independently by two authors (LW Shi and YH
Luo), and disagreements were resolved by discussion. The
details for the full search strategy were listed in a flow dia-
gram and Additional file 2.
Data extraction
Two authors (LW Shi and YH Luo) independently ex-
tracted information on patients, methods, interventions,
outcomes and results using a data extraction form de-
signed for this review. For dichotomous outcomes, we
extracted the number of events and the total number of
participants for each group. For continuous outcomes,
we abstracted mean changes, standard deviations and
the total number for each study. The data extraction
form included the following items: (1) general informa-
tion: title, authors, year of publication, and source; (2)
trial characteristics: design, duration of follow up,
method of randomization, allocation concealment, incom-
plete outcome data, blinding (patients, people administer-
ing treatment, outcome assessors); (3) intervention(s):
intervention(s) (dose, usage, duration and frequency),
comparison intervention(s) (dose, usage, duration and fre-
quency); (4) patients: total number and number in both
groups, baseline characteristics, diagnostic criteria, with-
drawals and losses to follow up (reasons, description); (5)
outcomes: outcomes specified above, any other outcomes
assessed, length of follow up, quality of reporting of out-
comes. Any disagreement was settled by discussion or by
consulting a third author (YM Xie and X Liao).
Quality assessment
The methodological quality of trials was assessed by Re-
view Manager Version 5.2 from the Cochrane Handbook
for Systematic Review of Interventions. We assessed the
methodological quality of each trial in terms of random se-
quence generation (selection bias), allocation concealment
(selection bias), blinding of participants and personnel
(performance bias), blinding of outcome assessment
(detection bias), incomplete outcome date (attrition bias),
selective reporting (reporting bias) and other bias. Then
we classified each quality component as “low”, “high”, “un-
clear”. If all the items were in low risk of bias, the trial
would be categorized into low risk of bias, if one or more
items were in high or unclear risk of bias, the trial would
be categorized into high or unclear risk of bias, respect-
ively. Low risk of bias represented a good quality. Any dis-
agreement was settled by discussion or by consulting a
third author (YM Xie and X Liao).
Data synthesis and analysis
Meta-analysis was performed by RevMan 5.2. For meas-
urement outcomes, D-value of the pre and post treatment
was used for statistical analysis. Dichotomous outcomes
were presented as risk ratio (RR) and 95 % confidence in-
tervals (CI), while continuous outcomes were expressed as
mean difference (MD) and 95 % confidence intervals (CI).
The I-square (I2) statistic, a quantitative measure of incon-
sistency across studies, was used to assess heterogeneity. If
the I2 statistic was equal to or less than 50 %, it suggested
that there was minor heterogeneity, fixed effect model
would be used to perform a meta-analysis. If the I2 statis-
tic was between 50 % to 90 %, it suggested that there was
substantial heterogeneity, random effect model would be
used to perform a meta-analysis. If the I2 statistic was
equal to or greater than 90 %, it suggested that there was
considerable heterogeneity, the meta-analysis wouldn’t be
performed, and instead the results of the trials would be
described. Subgroup analyses were performed to evaluate
the effects of SM plus conventional treatment in improv-
ing NYHA classification, LVEF or PaO2, and decreasing
BNP or PaCO2. If death and quality of life were reported
in the included trials, subgroup analyses were conducted
to assess the effects of SM plus conventional treatment on
death and quality of life. Publication bias was assessed
using a funnel plot if the group included more than 10
trials. Sensitivity analysis was performed to examine the
effects of excluding study subgroups, such as those
studies with lower methodological quality.
Results
Study selection
A total of 1434 records were identified after removing
duplicates. During the preliminary screening of the titles
and abstracts, 1373 records were removed. After full-
texts screening, 34 trials were excluded with the fol-
lowing reasons: participants didn’t meet the inclusion
criteria (n = 17), duplication (n = 3), no control group
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(n = 5), quasi-RCT (n = 3), non-RCT (n = 1), no data
available for extraction (n = 3), and without reporting
relevant outcomes (n = 2). Finally, 27 RCTs of SM for
chronic cor pulmonale heart failure were included in
this systematic review. The detailed process of search
and selection was shown in Fig. 1.
Study characteristics
A total of 27 RCTs with 2045 participants were included
in this review. The treatment group consisted of 1055
patients, while the control group consisted of 990 pa-
tients. All the included trials were conducted in China,
and published in Chinese. Sample size of the included
trials ranged from 44 to 120, with the average number of
76 per trial. Only four trials [13–16] included more than
100 patients. About 65 % of the participants were males.
Although there was a wide variation in the age of sub-
jects (34–89 years), the included patients were mainly
elderly. Fifteen trials [13, 15, 17–29] reported the course
of chronic cor pulmonale with a wide variation. All
patients were diagnosed as chronic cor pulmonale heart
failure with NYHA classification from I to IV, most of
who were diagnosed as chronic cor pulmonale heart fail-
ure with NYHA classification from II to IV.
The treatment group used SM combined with the
same conventional treatment as control group. The dose
of SM varied from 10 ml to 100 ml, most of which was
from 30 ml to 60 ml. Shenmai injection (SM) was ad-
ministered as intravenous drip in all included trials. Two
trials [16, 30] did not mention solvent. One trial [13]
used SM 1.0 ml/(kg · d) by intravenous drip without
solvent. One trial [17] used SM 100 ml by intravenous
drip without solvent. The other 23 trials used 0.9 % nor-
mal saline or 5 % glucose with the volume from 100 ml
to 250 ml as the solvent for SM. Shenmai injection (SM)
was used once daily in all included trials, except one trial
[15], in which SM was used twice daily. The intervention
time ranged from 7 to 15 days. The control group used
conventional medical treatment alone, including antibi-
otics, expectorants, antiasthmatic drugs, oxygen therapy,
Fig. 1 Flow diagram of study selection
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diuretics, digitalis, vasodilators, antiarrhythic drugs and
anticoagulants.
Only one trial [18] reported death. None of the in-
cluded trials reported quality of life. Twenty-five trials
[14–38] of the 27 included trials reported NYHA classi-
fication. Five trials [13, 20, 22, 37, 39] reported LVEF.
Four trials [15, 27, 28, 30] reported PaO2 and PaCO2.
Only two trials [13, 39] used BNP as outcome measure.
Six [15, 18, 27, 31, 37, 38] out of the 27 included trials
reported a total of 13 patients with ADEs or ADRs, in-
cluding pain, dizziness, palpitation, rash, dry mouth, poor
appetite, headache, nausea and vomiting. The details of
study characteristics were shown in Additional file 3.
Methodological quality
The methodological quality of the included trials was
generally poor. Two trials [13, 37] reported that random
sequence was generated by a random number table, the
remaining 25 trials only mentioned random alloca-
tion without any description about the method of
randomization. None of the trials described the allocation
concealment. Blinding of participants and personnel and
blinding of outcome assessment were not mentioned in all
included trials. None of the included trials reported with-
drawals or dropouts or performed an intention-to-treat
analysis. Selective reporting was generally unclear due to
the inaccessibility to the trial protocol. Other potential
sources of bias were unclear. None of the trials had a pre-
trial estimation of sample size. Therefore, the overall qual-
ity rating of all the included trials was graded as high risk
of bias. Sensitivity analysis was not performed due to all
included trials with generally low methodological quality.
More details of the trials were presented in Fig. 2.
Publication bias
Publication bias was assessed using a funnel plot based on
the NYHA classification reported in 25 trials [14–38]. The
funnel plot was asymmetrical indicating that potential
publication bias might influence the results of this review.
The publication bias might result from the following
reasons: small sample size, poor quality and a high pro-
portion of positive results. Funnel plot based on the data




Only one trial [18] reported death. This trial reported
that five patients were in a critical condition and eventu-
ally died during hospitalization, two from treatment
group and three from control group. However, there was
no statistically significant difference between SM plus con-
ventional treatment and conventional treatment alone on
death (RR, 0.65; 95 % CI, 0.11–3.67; P = 0.62). Other trials
didn’t report death during the scheduled treatment. None
of the trials reported the continued follow up after the
treatment period.
Quality of life
None of the included trials performed the assessment of
quality of life.
Secondary outcome measures
New York Heart Association (NYHA) classification
A total of 25 trials [14–38] with 1839 patients investi-
gated the effect of SM plus conventional treatment in
improving NYHA classification in patients with chronic
cor pulmonale heart failure. NYHA classification as a di-
chotomous outcome, the number of responders and the
total number of participants for each group were ex-
tracted to analyze risk ratio (RR), which was calculated
as the ratio between the proportion of responders in
treatment group and the proportion of responders in
control group. Responders were defined as an improve-
ment of at least one class on NYHA classification. The
I-square (I2) statistic based on the data for NYHA classi-
fication showed that there was no significant heterogen-
eity among 25 trials (I2 = 0 %, P = 0.89), and fixed effect
model was used to pool the results of these trials. The
pooled analysis of 25 trials indicated that SM plus
Fig. 2 Risk of bias
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conventional treatment showed greater improvement on
NYHA classification than conventional treatment alone
(RR, 1.26; 95 % CI, 1.20–1.32; P < 0.00001, Fig. 4).
Left ventricular ejection fraction (LVEF)
A total of five trials with 408 patients [13, 20, 22, 37, 39]
assessed the effect of SM plus conventional treatment in
improving LVEF in patients with chronic cor pulmonale
heart failure. The I-square (I2) statistic based on the data
for LVEF showed that there was substantial heterogen-
eity among these trials (I2 = 68 %, P = 0.01), and random
effect model was used to pool the results of these trials.
The meta-analysis indicated that there was a statistically
significant difference between SM plus conventional
treatment and conventional treatment alone on LVEF
(MD, 11.33; 95 % CI, 8.59–14.07; p < 0.00001, Fig. 5).
B-type natriuretic peptide (BNP)
Only two trials with 206 patients [13, 39] assessed the
effect of SM plus conventional treatment in decreasing
BNP in patients with chronic cor pulmonale heart fail-
ure. The I-square (I2) statistic based on the data for BNP
showed that there was considerable heterogeneity be-
tween two trials (I2 = 94 %, P < 0.0001). One trial [13] re-
ported that SM plus conventional treatment had better
effect than conventional treatment alone on BNP (MD,
88.70; 95 % CI, 74.28–103.12; p < 0.00001), the other
trial [39] reported that SM plus conventional treatment
was superior to conventional treatment alone to reduce
BNP (MD, 165; 95 % CI, 130.93–199.07; p < 0.00001)
Partial pressure of oxygen (PaO2) and carbon dioxide
(PaCO2)
Four trials with 301 patients [15, 27, 28, 30] assessed the
effects of SM plus conventional treatment in increasing
PaO2 and decreasing PaCO2 in patients with chronic
cor pulmonale heart failure. The I-square (I2) statistic
based on the data for PaO2 showed that there was sub-
stantial heterogeneity among these trials (I2 = 84 %, p =
0.0002), while the I-square (I2) statistic based on the data
for PaCO2 showed that there was no significant hetero-
geneity among these trials (I2 = 48 %, p = 0.13). Random
effect model was used to pool the results of these trials.
The pooled analysis indicated that there was a statisti-
cally significant difference between SM plus conven-
tional treatment and conventional treatment alone on
PaO2 (MD, 1.00; 95 % CI, 0.64–1.36; P < 0.00001, Fig. 6)
and PaCO2 (MD, 0.83; 95%CI, 0.58–1.08; p < 0.00001,
Fig. 6). It seemed that SM as an adjunct to conventional
medication could improve respiratory function.
Adverse drug events or reactions (ADEs or ADRs)
Six trials [15, 18, 27, 31, 37, 38] reported 13 patients
with ADEs or ADRs, eleven patients in treatment group
and two patients in control group. One trial [18] re-
ported that in treatment group three patients suffered
pain at the injection site and two patients suffered dizzi-
ness and palpitation, who recovered after slowing the in-
fusion speed of SM. There was one trial [31] reporting
one patient suffered dry mouth, who recovered after
slowing the infusion speed, which we regarded as ADE
due to unclear causal relationship judgment between the
event and SM. One trial [27] reported that ADR of rash
appeared in one patient in treatment group, which dis-
appeared after withdrawal of SM. One trial [15] re-
ported that ADR of scattered red rash occurred in one
patient in treatment group, which disappeared after
withdrawal of SM. One trial [37] reported that two pa-
tients in treatment group suffered poor appetite, who
recovered without special treatment. One trial [38] re-
ported that one patient in treatment group suffered pal-
pitation, and two patients in control group suffered
Fig. 3 Funnel plot of SM plus conventional treatment versus conventional treatment on NYHA classification. SM: Shenmai injection; NYHA classification:
New York Heart Association classification
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mild headache, palpitation, nausea and vomiting, and
poor appetite. After slowing the infusion speed, the pa-
tients recovered. We regarded these as ADEs, as this
trial [38] didn’t report any other details. Eleven trials
clearly reported that no ADEs or ADRs occurred in
their trials [14, 16, 17, 19, 20, 22, 24, 28, 32, 33, 35].
The remaining ten trials provided no data regarding
ADEs or ADRs [13, 21, 23, 25, 26, 29, 30, 34, 36, 39].
Discussion
Summary of evidence
This is the first comprehensive systematic review and
meta-analysis to assess the effects of SM as an adjuvant
treatment for chronic cor pulmonale heart failure with
NYHA classification from I to IV. In this systematic re-
view, only one trial reported death, and none of the in-
cluded trials reported quality of life. Thus evidence was
Fig. 4 The effect of SM plus conventional treatment versus conventional treatment on NYHA classification. The RR calculated as the ratio
between the proportion of responders in treatment group and the proportion of responders in control group and 95 % CI of fixed effect
model were used. Responders were defined as an improvement of at least one class on NYHA classification. The meta-analysis showed that
SM plus conventional treatment showed greater improvement on NYHA classification than conventional treatment alone(RR, 1.26; 95 % CI,
1.20–1.32; P < 0.00001). SM: Shenmai injection; NYHA classification: New York Heart Association classification; RR: Risk ratio; CI: Confidence interval
Fig. 5 The effect of SM plus conventional treatment versus conventional treatment on LVEF. The meta-analysis indicated that there was a statistically
significant difference between SM plus conventional treatment and conventional treatment alone on LVEF (MD, 11.33; 95 % CI, 8.59–14.07; p < 0.00001).
SM: Shenmai injection; LVEF: Left Ventricular Ejection Fraction; MD: Mean difference; CI: Confidence interval
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limited to make a conclusion on death and quality of
life. Due to a limited number of trials, poor methodo-
logical quality and significant heterogeneity among these
trials, it was hard to assess the effects of SM as an adju-
vant treatment in improving LVEF, PaO2 and decreasing
BNP, PaCO2. The main finding of present review was
that SM combined with conventional treatment ap-
peared to be more effective in improving NYHA classifi-
cation than conventional treatment alone. However, due
to generally poor methodological quality, small sample
size and publication bias, there was no evidence to sup-
port the routine use of SM as an adjuvant treatment for
chronic cor pulmonale heart failure. Another finding in-
dicated that SM seemed generally safe, but evidence was
limited to make a conclusion on the issue of safety be-
cause only 63 % studies mentioned the ADEs or ADRs.
Limitations
Although the meta-analysis suggested that SM could
have potential therapeutic effects and be relatively safe
for chronic cor pulmonale heart failure, a number of inher-
ent and methodological weaknesses should be addressed.
Firstly, randomization is necessary to avoid selection
bias. However, only two trials [13, 37] of the included
trials provided specific information on how the random
allocation was generated. None of the included trials re-
ported the allocation concealment. Indeed, inadequate
allocation concealment results in exaggerated estimates
of treatment effect. We didn’t contact the authors for
the method of randomization due to limited condition.
Therefore, we could not confirm that allocation was
truly random and well concealed. None of the trials
mentioned blinding. Placebo controlled or no treatment
is impossible in clinical trials due to ethic issues, as
chronic cor pulmonale heart failure is relatively severe.
All the included trials were generally of small sample
size, and none of the trials reported the method of calcu-
lation of the sample size and mentioned the possibility
of a type-II error occurring, which was likely to make re-
sults lack of power.
Secondly, none of the trials mentioned ethical issues
or whether the participants gave informed consent, ex-
cept one study [13]. Therefore, it seemed that reports of
the trials didn’t conform to the recommendations of the
Consolidated Standards of Reporting Trials (CONSORT)
statement [40].
Thirdly, the scheduled treatment period ranged from 7
to 15 days in the included trials. All of the trials assessed
the efficacy immediately after the termination of the
treatment period. None of the trials reported the contin-
ued follow up after the treatment period, and tried to in-
vestigate the effects that SM improved the prognosis of
chronic cor pulmonale heart failure and reduced the
times for admission. Therefore, the long-term effect of
SM treatment couldn’t be assessed due to lack of long-
term follow up.
Fourthly, the outcome measures of all trials were so
simple that there was no more or key information for
analysis. There was very limited evidence on the primary
outcome measures. Only one trial [18] reported death,
and none of the trials reported quality of life. The
NYHA classification was the most commonly used sec-
ondary outcome measure in the included trials, but it
was subjective for researchers to describe the improve-
ment of cardiac function class. The other secondary out-
come measures, including LVEF, BNP, PaO2 and PaCO2,
Fig. 6 The effect of SM plus conventional treatment versus conventional treatment in increasing PaO2 and decreasing PaCO2. D-value of the pre
and post treatment was used for statistical analysis. MD and 95 % CI of random effect model were calculated for these trials. The pooled analysis
indicated that there was a statistically significant difference between SM plus conventional treatment and conventional treatment alone on PaO2
(MD, 1.00; 95 % CI, 0.64–1.36; P < 0.00001) and PaCO2 (MD, 0.83; 95 % CI, 0.58–1.08; p < 0.00001). SM: Shenmai injection; PaO2: partial pressure of
oxygen; PaCO2: partial pressure of carbon dioxide; MD: Mean difference; CI: Confidence interval
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were reported in a limited number of trials with poor
methodological quality and significant heterogeneity.
Thus it was hard to assess the effects of SM in improv-
ing LVEF, respiratory function and decreasing BNP.
Fifthly, another limitation was publication bias which
was assessed by visual inspection of funnel plot. The
funnel plot was asymmetrical suggesting the possibility
of publication bias. Some researchers [41] reported that
some Asian countries including China published un-
usually high proportions of positive results. In this sys-
tematic review, there seemed to have great potential
publication bias of SM plus conventional treatment ver-
sus conventional treatment on NYHA classification,
which might influence the results of this review.
Lastly, special attention should be paid to adverse drug
events or reactions. Safety is a fundamental principle in
the provision of herbal medicines and herbal products
for health care. As more and more adverse drug events
of herbal medicines were found and reported. World
Health Organization (WHO) published WHO guidelines
on safety monitoring of herbal medicines in pharmacov-
igilance systems in 2004. However, in this systematic re-
view, ten trials [13, 21, 23, 25, 26, 29, 30, 34, 36, 39] did
not report the adverse drug events or reactions. Thus,
all adverse drug events must be reported by the re-
searchers participating in a clinical trial of SM according
to the recommendations of the CONSORT statement
[40] in the future.
Implication for practice
This systematic review provides weak evidence for the
efficacy and safety of SM as an adjuvant treatment for
chronic cor pulmonale heart failure, and a clinical rec-
ommendation cannot be warranted because of the gen-
erally low methodological quality and small sample size
of the included studies. Shenmai injection (SM) may
have beneficial effects on NYHA classification for
chronic cor pulmonale heart failure patients with NYHA
classification from I to IV. However, due to generally
poor methodological quality, small sample size and pub-
lication bias, there is no evidence supporting routine use
of SM as an adjunct to conventional medication for
chronic cor pulmonale heart failure. Therefore, high-
quality RCTs of SM for chronic cor pulmonale heart fail-
ure are required to confirm the effects reported in the
current systematic review.
Pattern differentiation is a unique TCM concept that
summarizes and differentiates the nature, location, and
pattern of diseases, which is the essential guide for
TCM therapy. The precisely tailoring Chinese herbal
prescription for individuals based on each individual
pattern can maximize its efficacy. For example, one
high-quality RCT of TCM as an adjuvant treatment for
chronic heart failure indicated that TCM staging-
differentiation treatment depending on pattern differ-
entiation as an adjunct to conventional medication
showed better effects than western medicine therapy
alone [42]. Therefore, we should combine pattern dif-
ferentiation with western medical diagnosis in modern
TCM research, which is beneficial to improve the ef-
fectiveness of the interventions [43]. In this systematic
review, none of the included trials mentioned the pat-
tern differentiation, except one trial [13], which re-
ported that the target population was diagnosed as
chronic cor pulmonale heart failure with the syndrome
of qi deficiency and blood stasis. However, Shenmai in-
jection (SM) is mainly used for chronic cor pulmonale
heart failure patients with qi-yin deficiency. Therefore,
future clinical trials should include patients who were
diagnosed as chronic cor pulmonale heart failure with
qi-yin deficiency.
Implication for future research
Clinical trials with both high methodological quality and
large sample size are required to assess the efficacy and
safety of SM as one adjuvant treatment for chronic cor
pulmonale heart failure. Sample size should be calcu-
lated by the proper statistical method and power or
type-II errors should be assessed. Further RCTs of SM
for chronic cor pulmonale heart failure should consider
more clinically relevant and objective outcome mea-
sures, such as death. Researchers of TCM should pay
greater attention to the methodological issues including
randomization, allocation concealment and blinding.
The quality of reporting of future trials should be im-
proved and reports of the trials should conform to the
recommendations of the CONSORT statement [40]. For
better evaluating the safety of traditional Chinese medi-
cine injection, it is essential to establish a clear monitoring
and reporting system for the adverse effects of traditional
Chinese medicine injection. Future trials should also give
consideration to including long-term evaluation of ef-
fectiveness and adverse effects of SM.
Conclusions
Shenmai injection (SM) combined with conventional
treatment appeared to be effective and relatively safe for
chronic cor pulmonale heart failure with NYHA classifi-
cation from I to IV. However, currently there was no
evidence supporting routine use of SM as an adjunct to
conventional medication for chronic cor pulmonale
heart failure due to the generally low quality and small
sample size of the included trials. Therefore, the efficacy
and safety of SM as an adjuvant treatment for chronic
cor pulmonale heart failure remain to be determined by
methodologically rigorous trials.
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